Skip to content

Comparing the Effect of Betamethasone and Ketorolac Injection on Treatment of De Quervain`s Tenosynovitis

Comparing the Effect of Betamethasone and Ketorolac Injection on Treatment of De Quervain`s Tenosynovitis in Diabetic Patients

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20220611055139N1
Enrollment
60
Registered
2022-08-19
Start date
2022-08-10
Completion date
Unknown
Last updated
2022-08-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

De Quervains tenosynovitis. Radial styloid tenosynovitis [de Quervain]

Interventions

Intervention 1: First Intervention group: Local injection of 1 cc betamthasone (1cc/4 mg-Darou Pakhsh Pharmaceutical Manufacturing Company) with 1 cc Lidocaine 2% approximately 2 cm proximal to radius

Sponsors

Oroumia University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: De Quervains Tenosynovitis Patients Diabetes mellitus Type 2 Patients Persons more than 18 yo ages

Exclusion criteria

Exclusion criteria: History of Allergic Reaction to Lidocaine ?Ketorolac (and other NSAIDs) ?Aspirin and Betamethasone History of Corticosteroids Injection in past 3 months History of surgery due to De Quervain`s Tenosynovitis in same wrist Pregnant ?Breastfeeding period and Patient with Gestational Diabetes Skin complications such as wounds, eczema or rash at the injection site Active infection at the injection site History of acute wrist trauma, history of wrist fracture, rheumatoid arthritis, uncontrolled diabetes Patients with type 1 diabetes

Design outcomes

Primary

MeasureTime frame
The amount of pain described by the patient. Timepoint: first session, 6 week, 3 months ,6 months after injection. Method of measurement: Visual Analogue Scale Score.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMehdi Zare

Oroumia University of Medical Sciences

Zare.mehdi8911215083@gmail.com+98 44 3345 9538

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026